Skip to main content

Moderna, Inc. (MRNA)

NASDAQ: MRNA · IEX Real-Time Price · USD
338.68 5.67 (1.70%)
Oct 21, 2021 1:59 PM EDT - Market open
Market Cap134.66B
Revenue (ttm)7.02B
Net Income (ttm)3.49B
Shares Out402.00M
EPS (ttm)8.46
PE Ratio40.01
Forward PE11.16
Ex-Dividend Daten/a
Previous Close333.01
Day's Range333.40 - 341.52
52-Week Range65.49 - 497.49
Price Target340.17 (+0.4%)
Est. Earnings DateNov 4, 2021

About MRNA

Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeu...

IPO DateDec 7, 2018
CEOStephane Bancel
Stock ExchangeNASDAQ
Ticker SymbolMRNA
Full Company Profile

Financial Performance

In 2020, Moderna's revenue was $803.40 million, an increase of 1,234.34% compared to the previous year's $60.21 million. Losses were -$747.06 million, 45.3% more than in 2019.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for Moderna stock is "Buy." The 12-month stock price forecast is 340.17, which is an increase of 0.44% from the latest price.

Price Target
(0.44% upside)
Analyst Consensus: Buy


Here is why you need to mix and match Moderna and J&J COVID-19 booster shots

TThe US health regulators have widened the country's COVID-19 vaccine campaign after the FDA-approved booster shots for Moderna Inc. (NASDAQ: MRNA) and Johnson & Johnson (NYSE: JNJ) vaccines. The FDA al...

Other symbols:JNJ
39 minutes ago - Invezz

Corona Doom 2.0: Carter Worth Warns That Vaccine-Maker Moderna May Have Further To Fall. What To Do If You're Long.

Moderna: Look Out Below? COVID-19 vaccine maker Moderna, Inc. (NASDAQ: MRNA) was our top name in late August.

2 hours ago - Benzinga

FDA authorizes Moderna, J&J Covid boosters as Pfizer posts new efficacy data

CNBC's Meg Tirrell joins 'Squawk Box' to report on the FDA's latest authorization for Covid-19 booster shots from Moderna and Johnson & Johnson, as well as Pfizer's latest booster efficacy data.

Other symbols:JNJPFE
5 hours ago - CNBC Television

Baillie Gifford Trimmed Positions In Alibaba, Tesla, Nio, Moderna In Q3, Here's What It Bought Instead

Investment firm Baillie Gifford lowered exposure in Tesla Inc (NASDAQ:TSLA), Alibaba Group Holding (NYSE:BABA) and Nio Inc (NYSE:NIO) in the third quarter and snapped up shares in vaccine maker Moderna ...

Other symbols:BABANIO
9 hours ago - Benzinga

FDA Approves Moderna, Johnson & Johnson Booster And 'Mix And Match' COVID-19 Shots

The U.S. Food and Drug Administration on Wednesday approved booster shots of Moderna Inc.'s (NASDAQ: MRNA) and Jonson & Johnson's (NYSE: JNJ) COVID-19 vaccines as well as authorized “mixing and matching...

Other symbols:JNJ
10 hours ago - Benzinga

FDA authorizes Moderna, Johnson & Johnson booster shots for many Americans

The administration also said it'll allow eligible people to "mix and match" different COVID-19 shots when they get their booster.

Other symbols:JNJ
19 hours ago - CNET

FDA clears Covid boosters for J&J, Moderna and allows 'mix and match' shots

Meg Tirrell joins 'Closing Bell' to report the FDA has issued Covid boosters for Moderna and J&J. The eligibility groups for Moderna and Pfizer boosters currently remain the same.

Other symbols:JNJ
20 hours ago - CNBC Television

FDA Approves Moderna And J&J Covid Booster Shots, Signs Off On Mix-And-Match Approach — Here's Who Is Eligible

All three Covid-19 vaccines now have booster shots authorized — but eligibility for extra doses depends on the specific vaccine.

Other symbols:JNJ
20 hours ago - Forbes

Here's Why Moderna's Growth May Be Just Getting Started

The company's COVID-19 vaccine might have set the stage for something big.

1 day ago - The Motley Fool

3 Biotech Stocks That Are Ridiculously Overpriced

They've risen too far, too quickly.

Other symbols:OCGNSAVA
1 day ago - The Motley Fool

Recent Weakness May Mean Opportunity With Moderna Stock

If you already own MRNA stock, it's too early to sell. If you do not yet own it?

1 day ago - InvestorPlace

Which Vaccine Stock Will Benefit Most From FDA's "Mix And Match" Approval?

On Tuesday, it became clear that the FDA plans to allow for a “mix and match” approach to vaccine booster shots, allowing—as the Europeans have recommended—people who have been vaccinated against Covid-...

Other symbols:JNJPFE
1 day ago - Benzinga

Has Moderna (MRNA) Outpaced Other Medical Stocks This Year?

Is (MRNA) Outperforming Other Medical Stocks This Year?

2 days ago - Zacks Investment Research

Moderna Stock Rose 6% Last Week. What's Next?

Moderna stock gained almost 6% over the last week (five trading days) outperforming the broader S&P 500 which was up about 2% over the same period. The recent gains come amid some upgrades on the stock ...

2 days ago - Forbes

Why Johnson & Johnson Will Be a Bigger Winner With Boosters Than Pfizer and Moderna

At least initially. It could be a different story over the longer term.

Other symbols:JNJPFE
2 days ago - The Motley Fool

Is the biotech sell-off a buying opportunity

Jared Holz, Oppenheimer, on whether the dip in biotech is an opportunity for investors. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour, Karen Finerman and Jeff Mills.

2 days ago - CNBC Television

Decision On Moderna's COVID-19 Vaccine For Adolescents Delayed - What You Need To Know

The FDA is delaying its decision to authorize Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine for adolescents to assess the risk of a rare inflammatory heart condition, Wall Street Journal reported citing...

2 days ago - Benzinga

J&J, Moderna COVID-19 Booster Jabs Near FDA Authorization

The FDA's Vaccines and Related Biological Products advisory committee recommends emergency use authorization for booster doses of J&J and Moderna's COVID-19 vaccines for use in certain adults.

Other symbols:JNJ
2 days ago - Zacks Investment Research

Why Moderna Shares Are Rebounding From Friday's Losses

Moderna, Inc. (NASDAQ:MRNA) shares have followed a downtrend ever since completing a double top formation in late September. After bottoming in early October, the stock reversed course and moved higher ...

3 days ago - Benzinga

Why Moderna Stock Is Rising Today

There's a super-bullish estimate for Moderna's 2022 sales.

3 days ago - The Motley Fool

Zillow, Disney, And Moderna Are Dealing With Tougher Outlooks

Bond investors have a lot on their plate with rising oil prices, a hawkish Bank of England, and hedge fund speculators. Can stocks build on last week's positive earnings?

Other symbols:ZZG
3 days ago - Forbes

Is Moderna a Good Healthcare Stock to Buy Now?

The vaccine maker has a promising pipeline but an expensive valuation.

3 days ago - The Motley Fool

Could Moderna Justify Its $129 Billion Valuation?

The company's COVID-19 vaccine has been a massive success, but how much is the underlying technology worth?

5 days ago - The Motley Fool